Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Hardy

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|January 1, 1989
A parametric study of space radiation exposures to critical body organs for low earth orbit missionsW Atwell, E R Beever, A C Hardy
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|October 1, 1994
Results of time-resolved radiation exposure measurements made during U.S. Shuttle missions with a tissue equivalent proportional counterM J Golightly, A C Hardy, K Hardy
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|January 1, 1992
Description, analysis and impact of major solar activity during recent U.S. Shuttle missionsM J Golightly, A C Hardy, W Atwell, et al.
British Journal of Haematology|October 1, 1995
Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndromeD Bouscary, M Fontenay-Roupie, S Chretien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO groupS Camilleri-Broët, A C Hardy-Bessard, A Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2009
Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLEC de la Fouchardière, R Largillier, Y Goubely, et al.
Gynecologic Oncology|February 24, 2009
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trialJ E Kurtz, A-C Hardy-Bessard, M Deslandres, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignanciesE C Brain, A Mita, P Soulié, et al.
Anticancer Research|March 9, 2012
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trialJ E Kurtz, G Freyer, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerL Cabel, F Berger, T Bachelot, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|January 1, 1989
A parametric study of space radiation exposures to critical body organs for low earth orbit missionsW Atwell, E R Beever, A C Hardy
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|October 1, 1994
Results of time-resolved radiation exposure measurements made during U.S. Shuttle missions with a tissue equivalent proportional counterM J Golightly, A C Hardy, K Hardy
Advances in Space Research : the Official Journal of the Committee on Space Research (COSPAR)|January 1, 1992
Description, analysis and impact of major solar activity during recent U.S. Shuttle missionsM J Golightly, A C Hardy, W Atwell, et al.
British Journal of Haematology|October 1, 1995
Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndromeD Bouscary, M Fontenay-Roupie, S Chretien, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO groupS Camilleri-Broët, A C Hardy-Bessard, A Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2009
Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLEC de la Fouchardière, R Largillier, Y Goubely, et al.
Gynecologic Oncology|February 24, 2009
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trialJ E Kurtz, A-C Hardy-Bessard, M Deslandres, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1997
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignanciesE C Brain, A Mita, P Soulié, et al.
Anticancer Research|March 9, 2012
Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trialJ E Kurtz, G Freyer, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerL Cabel, F Berger, T Bachelot, et al.
Pageof 2